Supporting the development of evidence-informed policy options: an economic evaluation of hypertension management in Ghana
Supporting the development of evidence-informed policy options: an economic evaluation of hypertension management in Ghana
Objectives
Universal healthcare coverage in low- and middle-income countries requires challenging resource allocation decisions. Health technology assessment is one important tool to support such decision making. The International Decision Support Initiative worked with the Ghanaian Ministry of Health to strengthen health technology assessment capacity building, identifying hypertension as a priority topic area for a relevant case study.
Methods
Based on guidance from a national technical working group of researchers and policy makers, an economic evaluation and budget impact analysis were undertaken for the main antihypertensive medicines used for uncomplicated, essential hypertension. The analysis aimed to address specific policy questions relevant to the National Health Insurance Scheme.
Results
The evaluation found that first-line management of essential hypertension with diuretics has an incremental cost per disability-adjusted life-year avoided of GH¢ 276 ($179 in 2017, 4% of gross national income per capita) compared with no treatment. Calcium channel blockers were more effective than diuretics but at a higher incremental cost: GH¢ 11 061 per disability-adjusted life-year avoided ($7189 in 2017; 160% of gross national income per capita). Diuretics provide better health outcomes at a lower cost than angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or beta-blockers. Budget impact analysis highlighted the potential for cost saving through enhanced price negotiation and increased use of better-value drugs. We also illustrate how savings could be reinvested to improve population health.
Conclusions
Economic evaluation enabled decision makers to assess hypertension medicines in a Ghanaian context and estimate the impact of using such evidence to change policy. This study contributes to addressing challenges associated with the drive for universal healthcare coverage in the context of constrained budgets.
Gad, Mohamed
8b8dd374-b976-470f-9483-09d73aa97d58
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Chalkidou, Kalipso
0dbe01e6-4baf-4d5b-88a9-99436ce07fd7
Asare, Brian
81573cf6-4a74-4c9a-8db3-ef5b3dbd6846
Lutterodt, Martha Gyansa
f28d63a4-3d74-4479-b5db-7e0dc25a5da5
Ruiz, Francis
aa032dc0-69df-407a-b45b-c9d134bb04c5
Gad, Mohamed
8b8dd374-b976-470f-9483-09d73aa97d58
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Chalkidou, Kalipso
0dbe01e6-4baf-4d5b-88a9-99436ce07fd7
Asare, Brian
81573cf6-4a74-4c9a-8db3-ef5b3dbd6846
Lutterodt, Martha Gyansa
f28d63a4-3d74-4479-b5db-7e0dc25a5da5
Ruiz, Francis
aa032dc0-69df-407a-b45b-c9d134bb04c5
Gad, Mohamed, Lord, Joanne, Chalkidou, Kalipso, Asare, Brian, Lutterodt, Martha Gyansa and Ruiz, Francis
(2019)
Supporting the development of evidence-informed policy options: an economic evaluation of hypertension management in Ghana.
Value in Health.
(doi:10.1016/j.jval.2019.09.2749).
Abstract
Objectives
Universal healthcare coverage in low- and middle-income countries requires challenging resource allocation decisions. Health technology assessment is one important tool to support such decision making. The International Decision Support Initiative worked with the Ghanaian Ministry of Health to strengthen health technology assessment capacity building, identifying hypertension as a priority topic area for a relevant case study.
Methods
Based on guidance from a national technical working group of researchers and policy makers, an economic evaluation and budget impact analysis were undertaken for the main antihypertensive medicines used for uncomplicated, essential hypertension. The analysis aimed to address specific policy questions relevant to the National Health Insurance Scheme.
Results
The evaluation found that first-line management of essential hypertension with diuretics has an incremental cost per disability-adjusted life-year avoided of GH¢ 276 ($179 in 2017, 4% of gross national income per capita) compared with no treatment. Calcium channel blockers were more effective than diuretics but at a higher incremental cost: GH¢ 11 061 per disability-adjusted life-year avoided ($7189 in 2017; 160% of gross national income per capita). Diuretics provide better health outcomes at a lower cost than angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or beta-blockers. Budget impact analysis highlighted the potential for cost saving through enhanced price negotiation and increased use of better-value drugs. We also illustrate how savings could be reinvested to improve population health.
Conclusions
Economic evaluation enabled decision makers to assess hypertension medicines in a Ghanaian context and estimate the impact of using such evidence to change policy. This study contributes to addressing challenges associated with the drive for universal healthcare coverage in the context of constrained budgets.
Text
VIH-2018-1024 Submitted version 12 July 2019
- Accepted Manuscript
More information
Accepted/In Press date: 1 January 2019
e-pub ahead of print date: 4 December 2019
Identifiers
Local EPrints ID: 437932
URI: http://eprints.soton.ac.uk/id/eprint/437932
ISSN: 1098-3015
PURE UUID: c06ea28b-ade4-4e99-ab95-2335767b3b23
Catalogue record
Date deposited: 24 Feb 2020 17:30
Last modified: 17 Mar 2024 05:12
Export record
Altmetrics
Contributors
Author:
Mohamed Gad
Author:
Kalipso Chalkidou
Author:
Brian Asare
Author:
Martha Gyansa Lutterodt
Author:
Francis Ruiz
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics